Publications in collaboration with researchers from Hacettepe University (50)

2024

  1. Clinical nutrition in primary care: ESPEN position paper

    Clinical Nutrition

  2. Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients

    The Lancet Infectious Diseases, Vol. 24, Núm. 1, pp. e59-e68

  3. Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies

    Journal of neurology, Vol. 271, Núm. 1, pp. 472-485

  4. Invasive Fungal Diseases in Adult Patients in Intensive Care Unit (FUNDICU): 2024 consensus definitions from ESGCIP, EFISG, ESICM, ECMM, MSGERC, ISAC, and ISHAM

    Intensive Care Medicine

  5. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

    The Lancet Oncology

2023

  1. Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies

    Rheumatology (United Kingdom), Vol. 62, Núm. 1, pp. 243-255

  2. Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis

    Multiple sclerosis (Houndmills, Basingstoke, England), Vol. 29, Núm. 7, pp. 875-883

  3. Gaps in clinical research in frontotemporal dementia: A call for diversity and disparities–focused research

    Alzheimer's and Dementia, Vol. 19, Núm. 12, pp. 5817-5836

  4. Predictors of treatment switching in the Big Multiple Sclerosis Data Network

    Frontiers in Neurology, Vol. 14

  5. Risk factors for infections caused by carbapenem-resistant Enterobacterales: an international matched case-control-control study (EURECA)

    eClinicalMedicine, Vol. 57

  6. The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

    Brain : a journal of neurology, Vol. 146, Núm. 11, pp. 4633-4644

2022

  1. Effect of Combination Antibiotic Empirical Therapy on Mortality in Neutropenic Cancer Patients with Pseudomonas aeruginosa Pneumonia

    Microorganisms, Vol. 10, Núm. 4

  2. Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO)

    Lung Cancer, Vol. 166, pp. 107-113

  3. Pseudomonas aeruginosa Bloodstream Infections in Patients with Cancer: Differences between Patients with Hematological Malignancies and Solid Tumors

    Pathogens, Vol. 11, Núm. 10

  4. Risk of infection in patients with hematological malignancies receiving CAR T-cell therapy: systematic review and meta-analysis

    Expert Review of Anti-Infective Therapy, Vol. 20, Núm. 11, pp. 1455-1476

2021

  1. Co-infections and superinfections complicating COVID-19 in cancer patients: A multicentre, international study

    Journal of Infection, Vol. 83, Núm. 3, pp. 306-313

  2. Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM

    The Lancet Infectious Diseases, Vol. 21, Núm. 12, pp. e375-e386

  3. Impact of the inclusion of an aminoglycoside to the initial empirical antibiotic therapy for gram-negative bloodstream infections in hematological neutropenic patients: a propensity-matched cohort study (AMINOLACTAM study)

    Antimicrobial Agents and Chemotherapy, Vol. 65, Núm. 8

  4. Invasive Aspergillosis Due to Aspergillus Section Usti: A Multicenter Retrospective Study

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 72, Núm. 8, pp. 1379-1385

  5. Nutrition education in medical schools (NEMS) project: Joining ESPEN and university point of view

    Clinical Nutrition, Vol. 40, Núm. 5, pp. 2754-2761